Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals

Neuropsychopharmacology

Volumn 36, Issue 5, 2011, Pages 950-959

  Ghahremani, Dara G ^a,f   Tabibnia, Golnaz ^b   Monterosso, John ^c   Hellemann, Gerhard ^a   Poldrack, Russell A ^d   London, Edythe D ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anterior cingulate; drug abuse; fMRI; learning; methamphetamine; modafinil

Indexed keywords

METHAMPHETAMINE; MODAFINIL; PLACEBO;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LEARNING; MALE; NEUROIMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; ASSOCIATION LEARNING; BENZHYDRYL COMPOUNDS; BRAIN; BRAIN MAPPING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEARNING DISORDERS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; OXYGEN; PHOTIC STIMULATION; SELF REPORT; TIME FACTORS; YOUNG ADULT;

EID: 79952765430     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.233     Document Type: Article

References (76)

1. Andersson J, Jenkinson M, Smith S (2007a). Non-linear optimisation. FMRIB Technical Report.
2. Andersson J, Jenkinson M, Smith S (2007b). Non-linear registration, aka Spatial normalisation. FMRIB Technical Report.
3. Baranski JV, Pigeau R, Dinich P, Jacobs I (2004). Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 19: 323-332. (Pubitemid 39106873)
4. Beckmann CF, Jenkinson M, Smith SM (2003). General multilevel linear modeling for group analysis in FMRI. Neuroimage 20: 1052-1063. (Pubitemid 37268124)
5. Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL et al (2002). Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 26: 376-386. (Pubitemid 34159215)
6. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG et al (2002). Brain metabolic changes during cigarette craving. Arch Gen Psychiatry 59: 1162-1172. (Pubitemid 35424027)
7. Buchel C, Holmes AP, Rees G, Friston KJ (1998). Characterizing stimulus-response functions using nonlinear regressors in parametric fMRI experiments. Neuroimage 8: 140-148. (Pubitemid 28471359)
8. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW et al (1999). Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409: 38-56. (Pubitemid 29242784)
9. Cools R, Clark L, Owen AM, Robbins TW (2002). Defining the neural mechanisms of probabilistic reversal learning using event-related functional magnetic resonance imaging. J Neurosci 22: 4563-4567. (Pubitemid 37465672)
10. Craig AD (2009). How do you feel-now? The anterior insula and human awareness. Nat Rev Neurosci 10: 59-70.
11. 0Brien CP (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211. (Pubitemid 40024415)
12. De La Garza II R, Zorick T, London ED, Newton TF (2010). Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methampheta-mine-dependent volunteers. Drug Alcohol Depend 106: 173-180.
13. Duvernoy HM, Bourgouin P (1999). The Human Brain: Surface, Three-Dimensional Sectional Anatomy with MRI, and Blood Supply, 2nd completely rev. and enl. edn. Springer: Wien, New York. p 491.
14. Filbey FM, Schacht JP, Myers US, Chavez RS, Hutchison KE (2009). Marijuana craving in the brain. Proc Natl Acad Sci USA 106: 13016-13021.
15. Finke K, Dodds CM, Bublak P, Regenthal R, Baumann F, Manly T et al (2010). Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Psychopharmacology (Berl) 210: 317-329.
16. First MB, Spitzer RL, Gibbon M, Williams J (1996). Structured Clinical Interview for DSM-IV Axis I Disorders- Patient Edition (SCID-IP, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute: New York, NY.
17. Garavan H (2010). Insula and drug cravings. Brain Struct Funct 214: 593-601.
18. Ghahremani DG, Lee B, Tabibnia G, Monterosso J, Poldrack RA, London ED (2009). Impulsive behavior and dopamine D2/3 receptor availability in healthy and MA-dependent individuals. In: 2009 Neuroscience Meeting Planner Society for Neuroscience (online).
19. Ghahremani DG, Monterosso J, Jentsch JD, Bilder RM, Poldrack RA (2010). Neural components underlying behavioral flexibility in human reversal learning. Cereb Cortex 20: 1843-1852.
20. Gonzales R, Mooney L, Rawson RA (2010). The methamphetamine problem in the United States. Annu Rev Public Health 31: 385-398.
21. Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P et al (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702-705.
22. Haber SN, Knutson B (2010). The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 35: 4-26.
23. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W et al (2010). Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 109: 20-29.
24. Jenkinson M, Bannister P, Brady M, Smith S (2002). Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17: 825-841. (Pubitemid 35317016)
25. Jenkinson M, Smith S (2001). A global optimisation method for robust affine registration of brain images. Med Image Anal 5: 143-156. (Pubitemid 35282800)
26. Kalechstein AD, De La Garza II R, Newton TF (2010). Modafinil administration improves working memory in methampheta-mine-dependent individuals who demonstrate baseline impairment. Am J Addict 19: 340-344.
27. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (2010). Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 69: 578-592.
28. Kurth F, Zilles K, Fox PT, Laird AR, Eickhoff SB (2010). A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis. Brain Struct Funct 214: 519-534.
29. Lee B, London ED, Poldrack RA, Farahi J, Nacca A, Monterosso JR et al (2009). Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J Neurosci 29: 14734-14740.
30. Lee NK, Rawson RA (2008). A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev 27: 309-317.
31. London ED, Berman SM, Voytek B, Simon SL, Mandelkern MA, Monterosso J et al (2005). Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 58: 770-778. (Pubitemid 41677415)
32. Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L et al (2006). Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319: 561-569.
33. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J et al (2008). Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 62: 91-100.
34. McGaugh J, Mancino MJ, Feldman Z, Chopra MP, Gentry WB, Cargile C et al (2009). Open-label pilot study of modafinil for methamphetamine dependence. J Clin Psychopharmacol 29: 488-491.
35. Minzenberg MJ, Carter CS (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsycho-pharmacology 33: 1477-1502. (Pubitemid 351684703)
36. Monterosso JR, Aron AR, Cordova X, Xu J, London ED (2005). Deficits in response inhibition associated with chronic metham-phetamine abuse. Drug Alcohol Depend 79: 273-277. (Pubitemid 40942119)
37. Naqvi NH, Bechara A (2009). The hidden island of addiction: the insula. Trends Neurosci 32: 56-67.
38. Naqvi NH, Rudrauf D, Damasio H, Bechara A (2007). Damage to the insula disrupts addiction to cigarette smoking. Science 315: 531-534. (Pubitemid 46175760)
39. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM (1998). The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25: 677-684.
40. Pluddemann A, Flisher AJ, McKetin R, Parry C, Lombard C (2010). Methamphetamine use, aggressive behavior and other mental health issues among high-school students in Cape Town, South Africa. Drug Alcohol Depend 109: 14-19.
41. Randall DC, Viswanath A, Bharania P, Elsabagh SM, Hartley DE, Shneerson JM et al (2005). Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 25: 175-179. (Pubitemid 40395097)
42. Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, Sambataro F et al (2010). Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology 35: 2101-2109.
43. Rawson RA, Condon TP (2007). Why do we need an addiction supplement focused on methamphetamine? Addiction 102(Suppl 1): 1-4. (Pubitemid 46328219)
44. Repantis D, Schlattmann P, Laisney O, Heuser I (2010). Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62: 187-206.
45. Robertson Jr P, Hellriegel ET (2003). Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 42: 123-137. (Pubitemid 36188553)
46. Sahakian B, Morein-Zamir S (2007). Professor's little helper. Nature 450: 1157-1159.
47. Salo R, Nordahl TE, Moore C, Waters C, Natsuaki Y, Galloway GP et al (2005). A dissociation in attentional control: evidence from methamphetamine dependence. Biol Psychiatry 57: 310-313. (Pubitemid 40187376)
48. Salo R, Ursu S, Buonocore MH, Leamon MH, Carter C (2009). Impaired prefrontal cortical function and disrupted adaptive cognitive control in methamphetamine abusers: a functional magnetic resonance imaging study. Biol Psychiatry 65: 706-709.
49. Schultz W, Dayan P, Montague PR (1997). A neural substrate of prediction and reward. Science 275: 1593-1599. (Pubitemid 27120526)
50. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH et al (2007). Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17: 275-297. (Pubitemid 47498174)
51. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J et al (2009). A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 104: 224-233.
52. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED (2010). Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 71: 335-344.
53. Sofuoglu M (2010). Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction 105: 38-48.
54. Spence SA, Green RD, Wilkinson ID, Hunter MD (2005). Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 187: 55-61. (Pubitemid 41002514)
55. Stix G (2009). Turbocharging the brain. Sci Am 301: 46-49, 52-45.
56. Tabibnia G, Monterosso JR, Baicy JK, Chakrapani S, Lee B, Aron AR et al (in press). Different forms of self-control share a neurocognitive substrate. J Neurosci.
57. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y et al (2004). Structural abnormalities in the brains of human subjects who use methamphetamine. J Neurosci 24: 6028-6036. (Pubitemid 38859399)
58. Tohka J, Foerde K, Aron AR, Tom SM, Toga AW, Poldrack RA (2008). Automatic independent component labeling for artifact removal in fMRI. Neuroimage 39: 1227-1245.
59. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a). Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder. Biol Psychiatry 55: 1031-1040. (Pubitemid 38581919)
60. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b). Modafinil improves cognition and atten-tional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29: 1363-1373. (Pubitemid 38780659)
61. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165: 260-269. (Pubitemid 36197601)
62. United Nations Office on Drugs and Crime (2009). World Drug Report 2009. UN Office on Drugs and Crime: Vienna.
63. Vocci FJ (2008). Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda. Exp Clin Psychopharmacol 16: 484-497.
64. Volkow ND, Chang L, Wang GJ, Fowler JS, Ding YS, Sedler M et al (2001a). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am J Psychiatry 158: 2015-2021. (Pubitemid 33104107)
65. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D et al (2001b). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382. (Pubitemid 32205193)
66. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
67. Wechsberg WM, Jones HE, Zule WA, Myers BJ, Browne FA, Kaufman MR et al (2010). Methamphetamine ('tik') use and its association with condom use among out-of-school females in Cape Town, South Africa. Am J Drug Alcohol Abuse 36: 208-213.
68. Wechsler D (2001). Wechsler Test of Adult Reading (WTAR). The Psychological Corporation: San Antonio.
69. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ (2002). Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacol-ogy (Berl) 159: 238-247. (Pubitemid 34143372)
70. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703. (Pubitemid 26191961)
71. Woolrich M (2008). Robust group analysis using outlier inference. Neuroimage 41: 286-301.
72. Woolrich MW, Behrens TE, Beckmann CF, Jenkinson M, Smith SM (2004). Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 21: 1732-1747. (Pubitemid 38446594)
73. Woolrich MW, Ripley BD, Brady M, Smith SM (2001). Temporal autocorrelation in univariate linear modeling of FMRI data. Neuroimage 14: 1370-1386. (Pubitemid 33124185)
74. Worsley KJ, Evans AC, Marrett S, Neelin P (1992). A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12: 900-918.
75. Young JW, Geyer MA (2010). Action of modafinil-increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry 67: 784-787.
76. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V et al (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.